BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2025-04-07 安徽来自江苏省

short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果

5 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2023-12-05 ms5000001058303842 来自北京

偏重的研究方向：分子生物学
经验分享：请问现在送审到多少号啦？我是7434#期刊论坛#

171 32

展开32条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2024-11-18 anan-prove 来自山东省

偏重的研究方向：小鼠模型;肿瘤免疫检查点
经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？

60 21

展开21条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2025-01-12 ms1000000724685965 来自上海

投了20天了，一点动静都没有。

28 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2025-01-16 ms1000001474584470 来自北京

投稿快一个月了，还是第一步，到底在干嘛他们，急死了

20 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2025-02-05 girlgo

偏重的研究方向：肿瘤;基础
经验分享：当天投当天under review是要被拒了吗？悲观了

24 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2024-10-13 ms1000001788822100 来自上海

审稿速度:6.0
经验分享：前后总共耗时2个多月
6月初提交差不多一周后送审
7.14 一审结束
8.29二审
9.17二审结束，仍有两三条小意见
9.20 返修后继续送审
9.25接受

73 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2024-10-26 ms1000001329023051

10.16投稿，现在还是submted to jounral

56 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2024-01-17 未知… 来自北京

偏重的研究方向：分子生物学;生物化学
经验分享：2023年11月28号投稿，至今仍然是submitted to Journal

77 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2259388, encodeId=c0432259388fb, content=short communication4.2号投稿，杂志会进行文字和图片查重。第二天就能知道查重结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a12f5512507, createdName=安徽, createdTime=Mon Apr 07 07:13:50 CST 2025, time=2025-04-07, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172975, encodeId=bbb521e297532, content=偏重的研究方向：分子生物学 经验分享：请问现在送审到多少号啦？我是7434<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=32, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=ms5000001058303842, createdTime=Tue Dec 05 09:17:45 CST 2023, time=2023-12-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2237535, encodeId=db55223e535c0, content=偏重的研究方向：小鼠模型;肿瘤免疫检查点 经验分享：想问问大家，送审多少号了？五个figure，做了三个小鼠模型，基本都是小鼠实验。创新性一般般，这种送审几率大不大呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffff9271833, createdName=anan-prove, createdTime=Mon Nov 18 08:30:50 CST 2024, time=2024-11-18, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2247712, encodeId=ee06224e712ba, content=投了20天了，一点动静都没有。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4ac6580068, createdName=ms1000000724685965, createdTime=Sun Jan 12 17:07:38 CST 2025, time=2025-01-12, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2248319, encodeId=7f8a224831955, content=投稿快一个月了，还是第一步，到底在干嘛他们，急死了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e099309520, createdName=ms1000001474584470, createdTime=Thu Jan 16 12:12:56 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2250629, encodeId=81d92250629b2, content=偏重的研究方向：肿瘤;基础 经验分享：当天投当天under review是要被拒了吗？悲观了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47142424112, createdName=girlgo, createdTime=Wed Feb 05 19:05:40 CST 2025, time=2025-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2230670, encodeId=ac4a22306e09d, content=审稿速度:6.0 经验分享：前后总共耗时2个多月 6月初提交差不多一周后送审 7.14 一审结束 8.29二审 9.17二审结束，仍有两三条小意见 9.20 返修后继续送审 9.25接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822100, createdTime=Sun Oct 13 21:45:29 CST 2024, time=2024-10-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2233285, encodeId=fd7b2233285ba, content=10.16投稿，现在还是submted to jounral, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dfd8575849, createdName=ms1000001329023051, createdTime=Sat Oct 26 19:34:23 CST 2024, time=2024-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2216361, encodeId=5c692216361e9, content=偏重的研究方向：肿瘤 经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=254, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Mon Jul 22 23:06:38 CST 2024, time=2024-07-22, status=1, ipAttribution=贵州省)]

2024-07-22 biocell160 来自贵州省

偏重的研究方向：肿瘤
经验分享：这个杂志现在是真的慢，投稿10天了是一点反馈都没有！

254 8

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务